- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Novo Nordisk Gets CDSCO Panel Nod To Import, Market Insulin Icodec to treat diabetes mellitus in adults
New Delhi: The drug major Novo Nordisk has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to import and market the Insulin Icodec 700 U/ml, 1050 U/1.5 ml, and 2100 U/3 ml for the indication of treatment of diabetes mellitus in adults.
However, this approval is subject to the condition that the drug major, Novo Nordisk, conduct an active post-market surveillance (PMS) study.
Furthermore, the expert panel stated that the drug shall be prescribed only by a registered endocrinologist or physician with a postgraduate qualification in medicine.
This came after the firm presented the product approval from the NRA of the country of origin, i.e., the EMA for grant of permission to import and market Insulin Icodec 700 U/ml, 1050 U/1.5 ml, and 2100 U/3 ml.
Insulin icodec is a once-weekly basal insulin analogue designed to cover the basal insulin requirements for a full week with a single subcutaneous injection. It is currently under investigation for the treatment of type 1 and 2 diabetes in the phase 3 ONWARDS programme.
Insulin remains the cornerstone of diabetes treatment. However, initiation of insulin therapy in type 2 diabetes is often delayed, despite uncontrolled blood sugar levels, leading to an increased risk of diabetes-related complications.
The insulin icodec molecule has been engineered by modifying human insulin to give it a prolonged half-life of approximately 7 days. Three amino acid substitutions have been introduced to provide molecular stability, minimise the enzymatic breakdown of insulin icodec, and reduce receptor-mediated clearance.
Insulin icodec is formulated at 700 units/mL to ensure that the injection volume is similar to that of once-daily basal insulin. It is designed to be injected subcutaneously once a week with an easy-to-use pen and optional digital support for personalized automated dose guidance.
At the recent SEC meeting for endocrinology and metabolism held on June 19, 2024, the expert panel reviewed the product approval from NRA of country of origin, i.e. EMA for grant of permission to import and market Insulin Icodec 700 U/ml, 1050 U/1.5 ml, 2100 U/3ml.
After detailed deliberation, the committee recommended the grant of permission to import and market Insulin Icodec 700 U/ml, 1050 U/1.5 ml, and 2100 U/3 ml for the indication of treatment of diabetes mellitus in adults with the following conditions:
Accordingly, the expert panel suggested that the firm submit an active PMS study protocol within three months of the grant of marketing authorization permission and a revised PI of the product to CDSCO for approval.
Also Read:CDSCO Panel Approves AstraZeneca pharma's Protocol Amendment proposal to study Anifrolumab
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751